Below is the information acquired on ABBVIE INC., which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 10 July 2021

Description of economic activities

Manufacture of pharmaceutical preparations (NACE2 2120)

The company is a research-based pharmaceuticals business that is engaged in the discovery, development, manufacture, and sale of a line of pharmaceuticals and biologics worldwide. It was established in 2012 and conducts business activities from its registered office in North Chicago, Illinois, United States.The company's principal products are HUMIRA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease as well as ulcerative colitis, and axial spondyloarthritis; Kaletra used in the treatment of HIV infection; Lupron used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia; Synagis, a syncytial virus prevention product used to protect infants from severe respiratory disease; AndroGel for the treatment of adult males who have low testosterone; sevoflurane, an anesthesia product; Zemplar for the prevention and treatment of secondary hyperparathyroidism associated with stage 3, 4, or 5 chronic kidney disease; Synthroid used for the treatment of hypothyroidism; Creon for the treatment of pancreatic exocrine insufficiency; and TriCor, Trilipix, Simcor, and Niaspan for the treatment of dyslipidemia. It also has a pipeline of new medicines consisting of approximately 20 compounds or indications in Phase II or Phase III development in medical specialties, such as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. In addition, the company offers other products, such as Duodopa, a levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease. It sells its products directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers.
  • ABBVIE INC.

  • United States of America (US)
  • Company type: Corporate
  • Parent company: N/A
  • Chief Executive Officer (CEO): Mr Richard A. Gonzalez
  • CEO Total remuneration: 19.564.505,506
  • Website: www.abbvie.com

Financial data

Number of employees

47,000
30,000
30,000
29,000

Revenue 1

37
30
29
24

EBIT 1

10
11
6
8

EBITDA 1

15
13
12
9

1 numbers are in millions

  • RepRisk Indicator (last month):  25

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

Standards and certifications

  • Global Compact: N/A
  • CDP (Carbon Disclosure Project): N/A
  • Modern Slavery Statement: N/A
  • Transparency Index: N/A
  • SA8000 Social Accountability: N/A
  • Integrated report: N/A
  • ISO26000: N/A
  • OECD Guidelines: N/A
  • Social Development Goals (SDGs): N/A

Global Reporting Initiative certification

  • Global Reporting Initiative standards: N/A
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

  • Corporate Social Responsability:
    N/A
  • Accessibility: N/A

Other resources

Policies

  • Training policy: N/A
  • Policy to protect the right to health and safety in the workplaces where the company operates: N/A
  • Policy to protect the right to health and safety in the workplaces in the supply chain: N/A
  • Diversity policy: N/A

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC: N/A
  • D. 89/391/EEC: N/A
  • D. 98/59/EC: N/A
  • D. 2000/43/EC: N/A
  • D. 2000/78/EC: N/A
  • D. 2001/23/EC: N/A
  • Council D. 2001/86/EC: N/A
  • D. 2002/14/EC: N/A
  • D. 2002/73/EC: N/A
  • Council D. 2003/72/EC: N/A
  • EP and Council D. 2005/56/EC: N/A
  • D. 2009/38/EC: N/A
  • D. 2004/25/EC: N/A
  • D. 2011/35/EU: N/A

Presence in main rankings

  • Global 100 Most Sustainable Corporations: N/A
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A

Reference trade unions